Ozempic, Wegovy, and the New Compliance Risks for Providers

Start
Diabetes and obesity drugs have skyrocketed in popularity as of late. According to a report released by Trilliant Health in September 2023, healthcare providers in the United States wrote more than 9 million prescriptions for Ozempic, Wegovy, and similar drugs in the last three months of 2022, with prescriptions rising 300% between 2020 and 2022….
By: Dentons
Previous Story

Time for Employers to Complete California Privacy Rights Act Compliance as Court of Appeal Lifts Injunction on Enforcement

Next Story

San Francisco Releases Generative AI Guidelines for City Workers